Safety data sheet - template
SAFETY DATA SHEET
SECTION 1: IDENTIFICATION OF THE SUBSTANCE AND SUPPLIER
For the control of albendazole sensitive roundworms, tapeworms, lungworms and adult fluke in sheep.
Phone: +64 9 980 1600 Fax: +64 9 980 1601
National Poisons Centre: 0800 764 766 (0800 POISON) Fire Service, Ambulance: Dial 111
Date of preparation:
SECTION 2: COMPOSITION/INFORMATION ON INGREDIENTS
SECTION 3: HAZARDS IDENTIFICATION
Priority and secondary
Risk and safety phrases:
6.3B May cause mild skin irritation. Avoid skin contact. 6.5B Repeated exposure may cause skin allergy. Avoid skin contact.
6.6B Albendazole possibly may cause damage to genetic material.
6.8A Albendazole may affect development and/or reproduction. Handle with care.
6.9B Albendazole possibly may cause organ damage from repeated
oral exposure at high doses. Handle with care.
SECTION 4: FIRST AID MEASURES
Necessary first aid
For advice contact the National Poisons Centre on 0800
POISON (0800 764 766), or a doctor immediately.
Ingestion: If swallowed seek medical attention. Do NOT induce
Eye Contact: If splashed in eyes wash out immediately with water. Skin Contact: If skin or hair contact occurs remove contaminated
clothing and flush skin and hair with running water. Inhalation: Remove to fresh air.
Observe good work practices and avoid skin contact. Wash hands and exposed skin before meals and after use. Do not eat or drink
while using. Launder protective clothing separately from other
Notes for medical personnel:
Apply symptomatic therapy. Note the nature of the product
(possible mutagen, reproductive/developmental toxin)
SAFETY DATA SHEET
SECTION 5: FIRE FIGHTING MEASURES
Type of hazard:
Non flammable, Non combustible, Non explosive
Fire hazard properties:
Albendazole Sheep is not classified as flammable, and will not
support combustion. Hazardous fumes when heated to
Extinguishing media and
Treat the fire as for the other materials present. Do not allow water
When fighting a major fire wear full protective clothing including
SECTION 6: ACCIDENTAL RELEASE MEASURES
Wear suitable protective clothing. Restrict access to contaminated area. Contain the spill and prevent further dispersion. Retrieve
intact containers from site. Place damaged containers into containment devices. Absorb spills with inert material and place in
waste containers. Wash the area with water and absorb with further
inert material. Collect spilled material and place in sealable
containers for subsequent disposal. Avoid contamination of water courses or sewers. Dispose of waste safely
SECTION 7: HANDLING AND STORAGE
Precautions for safe
Apply with well-maintained and calibrated equipment. Handle with
Conditions for safe storage:
Store in a cool place with lid on. Keep out of reach of children.
Store site requirements:
This substance is subject to a requirement for an emergency management plan and secondary containment, whenever it is held
in quantities of 1000L or more. See Hazardous Substances
(Emergency management) regulations 25 to 42.
Packaging Schedule 3 for quantities >1L (Hazardous Substances
Packaging Regulations 2001. UN Packing Group III.
SECTION 8: EXPOSURE CONTROL/PERSONAL PROTECTION
Application in the workplace:
Prevent exposure by using engineering controls, personal protective
equipment and work practices that prevent skin contact.
Exposure standards outside
Ensure that ventilation maintains dust levels below WES,
Clothing should consist of overalls with long sleeves and impervious
SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES
SAFETY DATA SHEET
Specify product data:
Appearance: White to off-white suspension
Specific gravity: ∼1.0 g/ mL Boiling Point: ca. 100° C
Vapour Pressure: NA Solubility in Water: Albendazole is insoluble
SECTION 10: STABILITY AND REACTIVITY
Stability of the substance:
Stable under normal conditions of use and storage.
Conditions to avoid:
Material to avoid:
No hazardous products are expected, except when heated to
Components are not expected to form hazardous polymers.
SECTION 11: TOXICOLOGICAL INFORMATION
Data and interpretation:
Albendazole Sheep: May cause mild skin irritation. Repeated
exposure may cause skin allergy. Danger of serious damage to health by prolonged exposure if swallowed. Albendazole possibly
may cause damage to genetic material. Albendazole may affect
development and/or reproduction. Albendazole possibly may cause
organ damage from repeated oral exposure at high doses.
Albendazole: Benzimidazoles prevent tubulin polymerisation or spindle movement and their administration can result in aneuploidy.
They are weak mutagens. Albendazole has low to moderate acute
oral toxicity [LD50 (oral, rabbit) 500-1250mg/kg; LD50 (oral, rat)
1320-2400mg/kg; LD50 (oral, mice) >3000mg/kg]. Identified as a
potential skin sensitiser by a positive result in a guinea pig
maximisation test. In repeated dose studies toxic effects included
reduced weight gain, reduced erythrocyte and leucocyte counts, decreased testes and uterine weights, slight increases in relative
liver and kidney weights, and sternal bone marrow hypocellularity
(lowest NOAEL 5mg/kg/day). Teratogenicity (visceral, craniofacial and bone defects) has been demonstrated in animal studies (lowest
SECTION 12: ENVIRONMENTAL INFORMATION
Data organisation :
Albendazole: Albendazole may be toxic to terrestrial vertebrates based on LD50 data [LD50 (oral, rabbit) 500-1250mg/kg]. Not toxic
to fish or honey bees. The potential for bioaccumulation is low and
benzimidazoles are degraded in soil and probably also in water.
Environmental risk and
SECTION 13: DISPOSAL CONSIDERATIONS
Disposal information :
Preferably dispose of the product by use. Otherwise dispose of
product and packaging at an approved landfill or other approved
SAFETY DATA SHEET
facility. Burn empty container in an appropriate incinerator, if
circumstances such as wind direction permit. Otherwise crush or
puncture and bury in a suitable landfill. Do NOT use container for
SECTION 14: TRANSPORT INFORMATION
Not classified as dangerous for rail, road, air or sea transport.
The maximum quantity per package of this substance allowed for
SECTION 15: REGULATORY INFORMATION
Registered pursuant to the ACVM Act 1997, No. A6520 See www.nzfsa.govt.nz/acvm for registration conditions
Approved pursuant to the HSNO Act, Approval Code HSR002240 See www.ermanz.govt.nz for approval conditions
SDS is required for quantities greater than or equal to 0.1L
HSNO and ACVM controls:
List exposure limits:
SECTION 16: OTHER INFORMATION
For product information visit the Merial website www.merial.co.nz While the information set forth is believed to be accurate as of the
date hereof, MERIAL NZ LTD. makes no warranty with respect hereto and disclaims all liability from reliance thereon.
Analysis of patient data from the Global Health Partnership mobile clinic at Kipsongo, Kitale, Kenya on 27 July 2011 Myer Glickman MFPH FHRIM FBMIS Consultant Statistician Development and Health Informatics Ltd Introduction This report is a brief analysis of patient data collected at the Global Health Partnership mobile clinic held in Kipsongo, Kitale, Kenya on 27 July 2011.
Aetna considers the following injections or procedures medically necessary for the treatment of back pain; provided, however, that only 1 invasive modality or procedure will be considered medically necessary at a time. Epidural injections of corticosteroid preparations (e.g., Depo-Medrol), with or without added anesthetic agents, are considered medically necessary in the outpatient setting